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S U M M A R Y
In the early 1980s, donor deferrals targeting men who have sex with men (MSM) and other high-risk
groups were implemented in response to the outbreak of HIV/AIDS. It has now been three decades since
the implementation of these deferrals. We review the international experience with developing these
policies, which involves combining scientiﬁc evidence with ethical and moral concerns and the challenge
of moving from precautionary to risk management policies as scientiﬁc knowledge and technology
evolves. We provide key lessons that can guide blood policymakers as they confront potential new
threats to the safety of the blood system and also provide lessons to the wider public health community
on how best to incorporate precaution into the policymaking process.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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In the early 1980s, several countries were confronted with the
tragedy of HIV-contaminated blood. Tens of thousands of
individuals contracted HIV from blood transfusions, and in many
jurisdictions there was a loss of conﬁdence in the blood system’s
ability to protect the public from this and other risks.1 In response,
many nations rethought how they would manage risk in their
blood systems and new policies were implemented to protect the
blood supply from future such events. In the case of HIV
contamination, one such policy was the decision to defer donations
from men who have sex with men (MSM). However, the
implementation of this policy did not occur without controversy
and sparked a backlash from the MSM community, many of whom
believed the policy was discriminatory.2
Three decades have now passed since countries instituted these
policies. These policies have evolved over time as new evidence on* Corresponding author.
E-mail address: kwilson@ohri.ca (K. Wilson).
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http://dx.doi.org/10.1016/j.ijid.2013.09.016the risk of transfusion-transmitted HIV has become available, as
well as new technologies for detecting this risk. We review the
international experience with developing these policies, which
involves combining scientiﬁc evidence with ethical and moral
concerns, and discuss the challenge of adapting policy as scientiﬁc
knowledge and technology evolves.
2. Introduction of MSM policies/rationale at the time
The ﬁrst cases of what would become known as acquired
immunodeﬁciency syndrome (AIDS) were characterized in homo-
sexual men in mid-1981.3 By early 1982, despite a viral etiology
having not yet been identiﬁed, infection patterns had blood
operators and key stakeholders such as hemophiliacs, concerned
about the condition possibly being transfusion-transmissible. This
suspicion was furthered as transmission patterns were beginning
to resemble those of hepatitis B, i.e., transmission through sexual
contact and the inoculation of blood and blood products.3 By mid-
1982, more than 350 people with the disease had been described.4
At that time, AIDS was predominantly being diagnosed in MSM,
members of the Haitian community, non-medical intravenous
drug users (IVDU), and hemophiliacs.5 In response, blood operators
worldwide issued restrictions in the form of donor deferrals from
these high-risk groups, including MSM, since there was no bloodciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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the time. In 1984, HIV was identiﬁed as the cause of AIDS.6
3. Evolution of policies
The discovery of HIV and subsequent development of laborato-
ry testing for blood products began to alleviate some of the
scientiﬁc uncertainty surrounding the transfusion transmissibility
and magnitude of the risk of the HIV virus to the blood supply.6 The
introduction of nucleic acid testing (NAT), approximately 15 years
after the implementation of the ﬁrst MSM donor deferral policies,
greatly increased the effectiveness of laboratory screening for
transfusion-transmitted infections such as HIV, but also contrib-
uted to the complexity of policymaking. Many known transfusion-
transmitted infections were now detectable at an early stage and
thus the argument for the MSM deferral was not as compelling.
However, the continued persistence of a narrow time window
during which HIV could not be detected by NAT provided a
scientiﬁc rationale for maintaining donor deferral policies.7 There
was also theoretical concern about emerging transfusion-trans-
missible infections having a higher likelihood of developing
amongst the MSM populations. While rates of sexually transmitted
infections and transfusion-transmitted infections in this group are
generally higher than in the rest of the population,7 emerging
threats to the blood system, since the identiﬁcation of AIDS, such as
West Nile virus and variant Creutzfeldt–Jakob disease, have
demonstrated other reservoirs for infection.
4. From precaution to risk management
Current MSM policies reﬂect modern testing methods and the
attempt to balance the risks of contaminating the blood supply
against the increasingly articulated social risks of marginalization
through exclusion from participating in blood donation. The most
restrictive is the lifetime deferral from blood donation for any
male-to-male sexual contact. Slightly less restrictive is the lifetime
deferral for any MSM activity after 1977. Intermediate approaches
include donor deferrals for a ﬁxed period after high-risk behavior,
such as policies that defer donations for 6 months, 1, 5, or 10 years
from those who have engaged in male-to-male sexual behavior
(see Table 1). The least restrictive approach is to harmonize
policies for MSM with those for individuals with a history of any
risky sexual behavior regardless of orientation (as seen in Spain,
Italy, Poland, and Russia).
When the initial policies were introduced, there was consider-
able uncertainty concerning the risk posed for transfusion
transmissibility of the emerging virus. Although they were perhaps
not explicitly identiﬁed as such, the policies followed principles of
precaution, introducing measures to protect against a theoretical
risk. It is also apparent that the policies were necessary at theTable 1
Current position of international MSM donor deferral policies
Country Policy 
South Africa 6-month MS
Argentina, Australia, UK, Hungary, Sweden, Czech Republic, Brazil 12-month M
New Zealand, Canada 5-year MSM
USA, Germany, Switzerland, the Netherlands, Norway, Hong Kong,
Denmark, Finland, France, Mexico, Slovenia, and Iceland
Lifetime MS
Spain, Italy, Poland, Russia No speciﬁc M
MSM, men who have sex with men; NAT, nucleic acid testing; HCV, hepatitis C virus; time.8 As scientiﬁc evidence accumulated and the risk could be
better quantiﬁed, MSM deferral policies migrated from precaution
to risk management. This transition can be a difﬁcult and lengthy
process. The introduction of new technologies and the evolution of
scientiﬁc consensus on both biological and social harm outpace
policy changes in many instances. The process to change MSM
deferral policies often involves many government and external
consultations to address issues of the public’s perception of risk
and trust in the blood operators, as well as the evaluation of new
risks created by changing existing policies.
Pressure to liberalize MSM donor deferral policies has intensi-
ﬁed in many countries. It is unlikely that public pressure from
these groups will diminish without the issue being adequately
evaluated in terms of acceptability and feasibility of various
alternative screening approaches with both donor and advocacy
groups.9,10 It remains a challenge to strike a balance between
prioritizing the safety of the blood supply and the rights of groups
that are socially marginalized by the same protective policies.
Nevertheless, the following key messages can be taken away from
the experience with MSM donor deferral (Table 2).
First, these policies were necessary at the time of implementa-
tion. Continuing to use a strong precautionary approach to protect
the blood supply from emerging pathogens, and acting in advance
of deﬁnitive evidence of risk, is necessary and essential to
maintaining the safety of the blood supply in the future and the
conﬁdence of the public.
Second, once instituted these policies are difﬁcult to withdraw,
even when risks become quantiﬁed and new technologies improve
safety. Ease of removal is heavily inﬂuenced by the political and
human consequences of the tragedy in each jurisdiction. A
particularly tragic history can cast a shadow on the ability to
alter the policy as new evidence becomes available. This can result
in the maintenance of a policy even when it appears inconsistent
with the weight of new evidence and scientiﬁc consensus.
Third, there are invariably ethical and moral dimensions that
must be considered when making decisions in this area. These
aspects of policymaking must be considered in combination with
the scientiﬁc evidence but should not preclude re-evaluation of
policies in the face of changing scientiﬁc evidence.
Fourth, those jurisdictions that have effectively transitioned
policies have regular independent reviews of current policies and
staged removals of policies when evidence suggests risk is
decreased/eliminated.
5. Evaluating the impact of policy changes
It is too early to evaluate the impact of the different approaches to
changing the MSM donor deferral policies. The lack of data collected
before and after altering MSM deferral policies has previously been
cited as a barrier to assessing the safety implications concerningContributing reason for change from lifetime deferral
M donor deferral Implemented single sample NAT for HIV, HCV, HBV
SM donor deferral Harmonizing policy for risky sexual behavior
 donor deferral New Zealand: Implemented single sample NAT for HIV,
HBV, HCV
Canada: Risk analysis, and extensive consultation with
scientiﬁc experts and with patient and community
groups
M donor deferral Not applicable
SM deferral policy Deferrals are now based on time period following the
change of sexual partner, and assessment of risky
sexual behavior – regardless of orientation
HBV, hepatitis B virus.
Table 2
Evolution of MSM deferral policy in the USA, Canada, UK, South Africa, Australia, and New Zealand
Country Policy Changes
USA 1983 – lifetime deferral None
Canada 1983 – lifetime deferral suggestion Response was criticized, withdrew deferral suggestion
1985 – lifetime deferral mandated 2012 – submission to regulator to change to 5-year deferral
2013 – 5-year deferral 2013 – Regulator approval for 5-year deferral
UK (England, Wales, Scotland) 1985 – lifetime deferral 2011 – 12-month deferral
South Africa 2001 – 5-year deferral instituted by new national
blood service
2006 – 5-year deferral changed to 6-month deferral
Australia Individual states and territories all had their own
version of an indeﬁnite deferral
Rolling introduction of a 12-month deferral from 1996 to 2000
New Zealand 1998 – 10-year deferral 2008 – 5-year deferral
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new policies, several questions should be examined.
Perhaps most important is whether relaxing the MSM deferral
policies results in an increase in risk of transmission of HIV in the
blood supply. Some initial studies have demonstrated this not to be
the case and evidence is emerging to suggest that relaxing the
deferral from lifetime can improve donor compliance, which may
paradoxically reduce the risk of an HIV-positive donation entering
the blood supply.14–17 Blood systems also need to monitor future
emerging transfusion-transmissible pathogens to determine if
they did incubate in MSM and whether maintaining a restrictive
MSM deferral could have protected the blood supply from these
threats. To date, this appears not to have been the case.
Another important question pertaining to changing the MSM
policies is the potential impact on the donor pool. Models have
suggested that if MSM deferrals are changed from lifetime, there
would be an increase in eligible donors.18 A gain of youth donors
may also potentially be achieved by relaxing the deferral.19–21
Other areas that deserve examination include evaluating the
impact of changing donor deferral policies on social stigmatization
of the MSM population, as well as the public’s perception of the
safety of the blood supply.
6. Conclusions
Transfusion transmission of HIV and the subsequent response
was transformative to public health. The protection of the blood
supply from HIV and other transfusion-transmitted infections
helped precipitate more widespread policies in public health where
preventative actions were taken in advance of deﬁnitive evidence of
risk.22 The MSM donor deferral story has also demonstrated the
consequences of these policies on speciﬁc communities and has
highlighted the challenges associated with moving from policies
based on precaution to risk management policies – as new evidence
quantiﬁes risk and new technologies reduce the evidence for the
policies’ existence. These lessons can inform blood systems as they
address novel risks to the blood supply and are also useful to the
wider public health communities as they determine how best to
incorporate precaution into their policymaking process.
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